

MPO antibodies are formed when the immune system mistakenly attacks the myeloperoxidase enzyme, found inside neutrophils. These antibodies are also called p-ANCA (perinuclear anti-neutrophil cytoplasmic antibodies) due to their perinuclear staining pattern observed during immunofluorescence testing.
The MPO (p-ANCA) measures antibodies against the myeloperoxidase (MPO) enzyme, which is found in neutrophils (a type of white blood cell) that help fight infections. This test helps diagnose autoimmune diseases, such as GPA and other forms of vasculitis, monitor disease activity, guide treatment decisions, and rule out other conditions that cause similar symptoms, such as infections or other autoimmune diseases.
A doctor may advise a MPO (p-ANCA) when symptoms of autoimmune vasculitis are present. General symptoms may include fever, fatigue, headache, weight loss, aches, etc. Other symptoms depend on the affected body parts.
No special preparation is required for the MPO (p-ANCA). Patients should inform their doctor about all medications (e.g., immunosuppressants, steroids, etc.) and supplements (e.g., biotin, etc.) currently being taken, as some may affect test results, potentially requiring dosage adjustments or temporary discontinuation before the test.
Test result ranges are approximate and may differ slightly between labs, depending on the methodology and laboratory guidelines. Self-medication should be avoided, and a doctor should always be consulted to interpret results correctly.
The MPO (p-ANCA) is a blood test that measures autoantibodies targeting the myeloperoxidase (MPO) enzyme (located in neutrophils). These autoantibodies are associated with autoimmune vasculitis disorders, particularly granulomatosis with polyangiitis (GPA) and other forms of vasculitis, where the immune system mistakenly attacks small blood vessels. This test helps diagnose these diseases, track disease activity, evaluate treatment response, and predict flare-ups.
Active inflammation is typically indicated by high MPO (p-ANCA) levels, while a decline suggests treatment effectiveness. Results should, however, be interpreted alongside clinical symptoms, as not all individuals with these diseases test positive, and false positives may occur with other conditions, such as infections or inflammatory conditions.
The MPO (p-ANCA) is performed:
- To diagnose autoimmune diseases, such as granulomatosis with polyangiitis (GPA) and other forms of vasculitis.
- To monitor disease activity over time.
- To evaluate treatment effectiveness.
- To rule out infections or other autoimmune diseases with similar symptoms.
- To predict disease progression.
- No special preparation is required.























